World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 3

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Methodol. Sep 26, 2014; 4(3): 163-188
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.163

Table 6 Orphan diseases with the most orphan drug approvals

Disease	Drugdesignation	Drugsapproved
AIDS	57	8
Acute myeloid leukaemia	34	5
Ovarian cancer	34	4
Multiple myeloma	32	6
Glioma	29	4
Chronic myelogenous leukaemia	19	4
Acute lymphoblastic leukaemia	17	6
Pneumocystis carinii pneumonia	15	5
Respiratory distress syndrome, infant	14	6
Multiple sclerosis	14	5
Growth hormone deficiency	13	9
Idiopathic pulmonary hypertension	12	4
Kaposi's sarcoma	11	5
Malaria	11	4

Adapted from ref[48,49]. AIDS: Acquired immunodeficiency syndrome.

Citation: Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014; 4(3): 163-188
URL: https://www.wjgnet.com/2222-0682/full/v4/i3/163.htm
DOI: https://dx.doi.org/10.5662/wjm.v4.i3.163

Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014; 4(3): 163-188 [PMID: 25332915 DOI: 10.5662/wjm.v4.i3.163]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.